Acadia Pharmaceuticals (ACAD) Receivables - Other (2016 - 2025)
Acadia Pharmaceuticals (ACAD) has 13 years of Receivables - Other data on record, last reported at $26.8 million in Q4 2025.
- For Q4 2025, Receivables - Other rose 349.53% year-over-year to $26.8 million; the TTM value through Dec 2025 reached $26.8 million, up 349.53%, while the annual FY2025 figure was $26.8 million, 349.53% up from the prior year.
- Receivables - Other reached $26.8 million in Q4 2025 per ACAD's latest filing, up from $23.6 million in the prior quarter.
- Across five years, Receivables - Other topped out at $26.8 million in Q4 2025 and bottomed at $403000.0 in Q3 2022.
- Average Receivables - Other over 5 years is $6.0 million, with a median of $3.2 million recorded in 2023.
- Peak YoY movement for Receivables - Other: tumbled 80.99% in 2021, then surged 602.54% in 2024.
- A 5-year view of Receivables - Other shows it stood at $978000.0 in 2021, then dropped by 9.51% to $885000.0 in 2022, then surged by 361.36% to $4.1 million in 2023, then surged by 45.87% to $6.0 million in 2024, then skyrocketed by 349.53% to $26.8 million in 2025.
- Per Business Quant database, its latest 3 readings for Receivables - Other were $26.8 million in Q4 2025, $23.6 million in Q3 2025, and $12.2 million in Q2 2025.